<DOC>
	<DOCNO>NCT00962091</DOCNO>
	<brief_summary>This open-label , multicenter , phase 1 study evaluate safety pharmacokinetic property oral solution enteric-coated tablet ( ECT ) formulation MLN8237 patient advance solid tumor . This study conduct 3 part , A , B , C .</brief_summary>
	<brief_title>Study MLN8237 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : 18 year old Histologically cytologically confirm metastatic and/or advance solid tumor Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception abstain heterosexual Male patient agree practice effective barrier contraception agree abstain heterosexual intercourse Voluntary write consent Suitable venous access studyrequired blood sample Measurable disease Recovered effect prior antineoplastic therapy Patients meeting follow exclusion criterion enrol study : Female patient pregnant lactate Serious medical psychiatric illness could interfere protocol completion Major surgery within 14 day first dose MLN8237 Antineoplastic therapy , radiation therapy experimental therapy 21 day prior first dose MLN8237 Nitrosoureas mitomycinC within 6 week first dose MLN8237 . Autologous stem cell transplant within 3 month first dose MLN8237 , prior allogeneic stem cell transplant time . Active infection require systemic therapy , serious infection Inability swallow oral medication Gastrointestinal ( GI ) disease GI procedure could interfere oral absorption tolerance MLN8237 Symptomatic brain metastasis Uncontrolled cardiovascular condition Diagnosis treatment another malignancy within 2 year precede first dose study drug except nonmelanoma skin cancer situ malignancy completely resect Known history human immunodeficiency virus ( HIV ) infection , hepatitis B , hepatitis C Lactoseintolerant ( Parts A B ) Prior history metabolic acidosis ( Parts A B ) Use enzymeinducing antiepileptic drug phenytoin , carbamazepine phenobarbital , rifampin , rifabutin , rifapentine St. John 's wort within 14 day prior first dose MLN8237 A medical condition require use pancreatic enzyme ; daily , chronic , regular use proton pump inhibitor ( PPI ) ; histamine ( H2 ) receptor antagonist . Patients intermittently use medication must meet following : No use PPI within 7 day first dose MLN8237 No use H2 antagonist pancreatic enzyme within 24 hour first dose MLN8237 Patients require full systemic anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Area plasma concentration versus time curve ( AUC )</keyword>
	<keyword>Maximum plasma concentration ( Cmax )</keyword>
	<keyword>Area plasma concentration versus time curve zero time last quantifiable concentration ( AUC0-tlast )</keyword>
	<keyword>Confidence interval ( CI )</keyword>
	<keyword>Time first observe maximum plasma concentration ( Tmax )</keyword>
</DOC>